Onkologiepraxis Bellvue
Welcome,         Profile    Billing    Logout  
 0 Trials 
1 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bättig, Basil A
OGIPRO, NCT05234021: HER2-directed Biosimilar in Breast Cancer: Real World ePRO

Completed
N/A
52
Europe
OnkoZentrum Zürich AG, University of Zurich, Palleos Healthcare GmbH
HER2-positive Breast Cancer, Biosimilar, Patient Reported Outcome
06/23
06/23

Download Options